Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago.
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday
Apellis Pharmaceuticals (NASDAQ: APLS - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
